Myocardial perfusion imaging (MPI) is an effective technique used to study the left ventricular ejection function (LVEF), myocardial perfusion, wall motion, and wall thickening. Positron emission tomography (PET) and single photon emission computed tomography (SPECT) are two modalities that can be used to quantify the left global and regional perfusion at rest and stress. While PET and SPECT rely on similar principles to produce images, important differences in instrumentation and experimental applications are dictated by inherent differences in their respective physics of radioactive decay. With a sensitivity > 90% in combination with a high specificity, PET is today the best available nuclear imaging technique for the diagnosis of coronary artery disease (CAD). The short half-life of the perfusion tracers in combination with highly sophisticated hard- and software enables rapid PET studies with high patient throughput. Rubidium-82 (82Rb) is a PET perfusion imaging agent that has a shot half-life of 76 seconds which enables multiple sequential data acquisitions in a short duration of time. It also reduces the number of false-positive SPECT scans and artifacts from soft tissue attenuation due to the routine application of attenuation correction. However 82Rb PET imaging is under-utilized clinically due to difficulty optimizing the imaging parameters. The major challenge of 82Rb imaging is determining when to begin the image acquisition post infusion, as imaging too early results in images with high background (low contrast), and imaging too late results in noisy images due to low count statistics. 82Rb rest/stress dynamic and gated data from 16 patients were available for analysis. The FWHM of the 82Rb infusion, LV cavity and LV myocardial uptake in time activity curves were generated and compared to isolate the dominant parameter in determining image quality. The measured and actual infusion-time correlated only at rest (r = 0.93, P = 0.006). Splitting-time at rest and stress correlated (r = 0.74, P = 0.09). But the study was not able to identify a single dominant parameter that would determine the image quality due to the unpredictable nature of hemodynamics during the vasodilatory induced cardiovascular stress. First pass radionuclide angiography (FPRNA) is the gold standard for quantification of ejection fraction. We examined the quantification of the ejection function (LVEF) to determine whether the gated 82Rb PET data, using quantitative gated SPECT (QGS), would accurately predict changes in the chamber volume and correlated the results with those obtained from FPRNA technique. There was a good correlation between the resting FPRNA data and resting gated 82Rb QGS data (r= 0.81, P=0.0005) showing that this method can be applied to 82Rb PET.99mTc SPECT was considered the gold standard for this study, as it is the most widely used technique for myocardial perfusion imaging. The under-perfused area of the myocardium is defined as defect. 99mTc agents, 18F-FDG, and 82Rb can all be used for cardiac imaging 1-7. However, count rates, energy and camera differences can yield image differences that are independent of the actual biological distribution. We examined whether PET with an 82Rb-labeled tracer would provide information on defect size similar to that provided by 99mTc SPECT, using a cardiac phantom in which the true defect size is known. Since 82Rb has such a short half-life (76 seconds), filling and imaging a phantom was going be a great challenge. Hence 124I which is a high-energy radioisotope like 82Rb, was used in this phantom study as a surrogate for 82Rb. Static cardiac phantom studies with 99mTc, 18F and 124I (surrogate for 82Rb) were conducted. The percent defect sizes were measured and compared with the true defect size. Our results demonstrated that at 45% threshold, the measured defect size was representative of true defect size for 99mTc SPECT data. Using this threshold as the standard, we smoothed the 18F and 124I PET data until the measured defect size for PET was representative of the true defect size. An optimal filter cutoff frequency (Butterworth filter, cutoff = 0.80 cycles/pixel, order=5 at 45% threshold for 124I or 82Rb) was found for the PET data within the range of values studied, and this frequency was higher than the clinical norm for SPECT data. Our results also illustrated that the measured SPECT defect size varied greatly depending on the thresholds used to define a defect, whereas measure PET defect size was relatively constant over the range of cutoffs tested7. The optimal cutoff may depend on defect size, patient variability, and noise level. When assessing myocardial defect size, physical properties need to be taken into consideration, particularly when comparing images obtained using different nuclides (i.e. 82Rb or 99mTc agent perfusion and 18F FDG viability).

Abstract: Sunitinib (Sutent®) is a multitargeted, small molecule receptor tyrosine kinase inhibitor used as an anti-cancer drug. It has increased the overall survival rate of metastatic renal cell carcinoma patients as well as the survival time of patients with pancreatic neuroendocrine tumors. Although the clinical use of sunitinib is a significant leap forward in the therapy of those cancers, its induction of cardiac toxicity in a substantial fraction of patients remains a critical problem. Sunitinib may cause hypertension, arrhythmias, drop of the left ventricular ejection fraction and congestive heart failure, fatal in some cases. These side effects are a frequent reason for interruption of its use. The mechanism(s) underlying sunitinib cardiotoxicity are not fully understood. Similar to other receptor tyrosine kinase inhibitors, it binds to a large number of cellular kinases, thus it can affect multiple cellular processes. In vivo, the pattern of toxicity is complex and unpredictable, with symptomatic heart failure sometimes observed early during treatment. The pattern of events preceding the onset of symptomatic cardiac dysfunction during treatment is not established. This represents a significant problem for the clinical diagnosis of cardiovascular complications before they become symptomatic. The identification and early detection of those events would be highly-beneficial for the clinical management of anti-cancer therapy with sunitinib. Positron Emission Tomography (PET) is recognized for its ability to probe metabolic and functional aspects of myocardial function. Under the working concept that heart failure can occur early during sunitinib treatment, and may be sustained by early myocardial metabolic and structural alterations, we performed a study with the objective of assessing the use of PET for the early detection of sunitinib-induced ardiotoxicity. For this, we established a model of cardiotoxicity in C57BL/6 male mice given 80mg/Kg/day of sunitinib or water, orally for 4 weeks. General and cardiac toxicity were monitored by biochemical, microscopical (H&E, immunofluorescence and electron microscopy) as well as gene expression analyses and blood pressure measurements. PET scans were performed weekly using [superscript 11]C-acetate and [superscript 18]F-FDG to evaluated the myocardial blood flow (MBF), myocardial oxidative metabolism through the quantification of oxygen consumption (MVO[subscript 2]), glucose uptake (K[subscript i]), myocardial metabolic rate of glucose (MMRG) and the left ventricular ejection fractions (LVEF). We found that sunitibib was cardiotoxic as revealed by histopathology, immunostaining and electron microscopy. Signs of inflammation and tissue remodeling were found by gene expression analyses and collagen staining. No hypertension or renal damage were detected on the study. FDG-PET revealed an early decrease of the LVEF, indicative of cardiac dysfunction, which developed into grade-2 heart failure by the end of the study. However, no signs of alterations in cardiac metabolism were uncovered by FDG- or [superscript 11]C-acetate-PET. Our results hint that the onset of sunitinib-induced contractile dysfunction may occur in the absence of hypertension or overt metabolic damage and call for further studies with longer treatments to clearly mark the onset of metabolic cardiotoxicity. // Résumé: Le sunitinib est un inhibiteur de tyrosine kinase qui est utilisée comme agent anticancéreux. Bien que l'utilisation clinique du sunitinib représente une percée significative pour le traitement de certains cancers, ce médicament s’avère cardiotoxique chez plusieurs patients, une situation qui est problématique. Le sunitinib peut provoquer une hypertension, des arythmies, une chute de la fraction d'éjection ventriculaire gauche et une insuffisance cardiaque congestive qui peut être fatale. Le mécanisme responsable de la cardiotoxicité de sunitinib n’est pas encore bien compris. Comme plusieurs autres inhibiteurs des récepteurs de la tyrosine kinase, il se lie à un grand nombre de kinases et peut affecter de nombreux processus cellulaires. In vivo, les mécanismes responsables de la toxicité sont complexes et imprévisibles et une insuffisance cardiaque est parfois observée tôt pendant le traitement. La séquence des évènements menant à l'apparition d’une dysfonction cardiaque pendant le traitement n’est pas connue. Cela pose un problème important pour le diagnostic de complications cardiovasculaires avant qu'elles ne deviennent symptomatiques. Une identification précoce de ces événements néfastes serait très bénéfique pour le suivi du traitement au sunitinib. La tomographie d'émission par positrons (TEP) est une méthode reconnue pour l’évaluation du métabolisme et de la fonctionnalité du myocarde. Selon notre hypothèse de travail, une insuffisance cardiaque peut survenir rapidement pendant le traitement au sunitinib, elle est l’expression d’altérations structurelles et métaboliques au niveau du myocarde; ces modifications se produisent tôt pendant le traitement. Nous avons effectué une étude pour évaluer la faisabilité d’utiliser l’imagerie TEP pour la détection précoce de la cardiotoxicité induite par le sunitinib. La première étape a été de développer un modèle de cardiotoxicité chez des souris. L’induction de la cardiotoxicité s’est faite par administration orale pour une période de quatre semaines, soit de sunitinib 80mg/Kg/jour ou d'eau pour les souris contrôles. Le suivi inclut la mesure de la pression sanguine, l’évaluation des altérations biochimiques, l’expression de certains gènes et un examen histologique du myocarde. Un suivi par imagerie TEP a été effectué chaque semaine avec du [indice supérieur 11]C-acétate et du [indice supérieur 18]F-FDG afin d'évaluer le flux sanguin myocardique (MBF), le métabolisme oxydatif du myocarde incluant la consommation d'oxygène (MVO2), l'absorption du glucose (K[indice inférieur i]), le taux métabolique oxydatif du glucose (MMRG) ainsi que la fraction d'éjection ventriculaire gauche (FEVG). Les résultats que nous avons obtenus par histopathologie, immunocoloration et microscopie électronique montrent que notre modèle est capable d’induire une cardiotoxicité. Nous avons également observé des évidences d'inflammation et de remodelage tissulaire à partir de l’étude de l'expression de certains gènes et de l’analyse de l’accumulation de collagène. Nous n’avons pas observé d’hypertension ni de lésions rénales. La TEP avec [indice supérieur 18]FDG a montré une diminution rapide de la FEVG, une indication d’une dysfonction cardiaque qui a été classée comme insuffisance cardiaque de grade 2 à la fin de l'étude. Cependant, aucun signe de modifications du métabolisme cardiaque n’a été mis en évidence par TEP/[indice supérieur 18]FDG- ou TEP/[indice supérieur 11]C-acétate. Nos résultats laissent penser que l'apparition de la dysfonction contractile induite par sunitinib peut se produire en l'absence d'hypertension ou de dommages métaboliques manifestes. De nouvelles études avec des traitements plus longs permettraient peut être de mieux définir le début de la cardiotoxicité métabolique.

Echocardiography examination is an important and familiar method for heart`s examination. Echocardiography is used to assess the function of the heart during to check the heart disease. In an echocardiography examination, the heart´s flow rates, contractility (pumping capacity), wall thickness, and inner diameter can be examined. All these examinations are done with the help of evolution of the ultrasonic waves that the ultrasonic transducer sends out and receives. The transducer consists of piezoelectric crystals that can both transmit and receive ultrasonic waves with frequencies exceeding 20 kHz. The purpose of the study is to compare the measurement of the left ventricular ejection fraction (LVEF) between an experienced biomedical scientist (BMA) and a student. In addition to see how the image quality affects the result. The measurement was performed by using the Simpson method. The result was analyzed by using with a static method. The results were analyzed by using a paired t-test to see if there is any significant difference between the performance of a BMA and a student. The measurement was performed on apical 4-chamber and apical 2-chamber image. The study included 30 patients, both heart -healthy and cardiac patients of the genders. The result showed that there is a significant difference in the performance of LVEF- measurements between BMA and student, with lower values measured by the student. / Ekokardiografiundersökning är en viktig och vanlig metod vid undersökning av hjärtat. Ekokardiografi används för att bedöma hjärtats funktion vid utredning av hjärtsjukdomar. Vid en ekokardiografiundersökning kan hjärtats flödeshastigheter, kontraktilitet (pumpförmåga), väggtjocklek, och innerdiameter undersökas. Alla dessa undersökningar görs med hjälp av tolkning av ultraljudsvågorna som ultraljudsgivaren skickar ut och tar emot. Givaren består av piezoelektriska kristaller som kan både sända och tar emot ultraljudsvågor med frekvens på över 20 kHz. Syftet med denna studie är att jämföra mätningen av den vänstra ventrikulära ejektionsfraktion (LVEF) mellan en erfaren biomedicinsk analytiker (BMA) och en student samt att se hur bildkvalitén påverkar resultatet. Mätningen utfördes med Simpsons- metoden. Resultatet analyserades med hjälp av en statistisk metod. Resultatet analyserades med hjälp av parat t-test för att se om det finns någon signifikant skillnad mellan utförandet av en BMA och en student. Mätningen utfördes på apikala 4-kammarbilder och apikala 2-kammarblider. Studien inkluderade 30 patienter, både hjärtfriska och hjärtsjuka patienter av både könen. Resultatet visade att det finns en signifikant skillnad i utförande av LVEF- mätningar mellan BMA och student, med lägre uppmätta värden av studenten.

Ziel: Die Ergebnisse nach aortokoronarer Bypassoperation (CABG) unterscheiden sich bei Patienten mit schlechter linksventrikulärer Pumpfunktion deutlich von denen bei Patienten ohne Einschränkungen derselben. Das Ziel dieser Studie war die Untersuchung des Einflusses einer reduzierten linksventrikulären Ejektionsfraktion (LVEF), eines vergrößerten linksventrikulären enddiastolischen Volumenindexes (LVEDVI) und eines erhöhten linksventrikulären enddiastolischen Druckes (LVEDP) auf das postoperative "outcome". Material und Methodik: Im Rahmen dieser retrospektiven Studie wurden 148 Patienten mit einer koronaren Herzkrankheit (KHK) und eingeschränkter Ejektionsfraktion (EF / Aim: Results of coronary artery bypass grafting (CABG) in patients with poor left ventricular ejection fraction (LVEF) differ from those in patients with normal LVEF. The aim of the study was a investigation into the influence of reduced LVEF, augmented left ventricular enddiastolic volume index (LVEDVI) and elevated left ventricular enddiastolic pressure (LVEDP) on the outcome of CABG. Methods: 148 Patients with LVEF < 50% underwent CABG. Exercise tolerance and LVEF were determined pre- and postoperatively. Three subgroups were built to distinguish the influence of reduced LVEF on postoperative outcome. Group I: LVEF < 30%, group II: 30% < LVEF < 40%, group III: 40% < LVEF < 50%. Results: Exercise tolerance rised from a preoperatively mean of 70 Watt to 97 Watt postoperatively. Mean NYHA class was 2,7 pre- and 1,7 postoperatively. There were no significant differences in the results of the three subgroups. Perioperative mortality in group I was 6,3%. Actuarial 1 and 2 years survival in this group is at 81 and 70% respectively. These results differ clearly from those of group II and III. Perioperativ mortality was 2,2% in group II and 1,4% in group III. Actuarial 1 and 2 years survival is at 93 and 84% in group II and at 95 and 83% in group III. There was no difference in postoperative outcome of patients with LVEDP > 12mmHg in comparison to patients with LVEDP < 12mmHg. Patients with LVEDVI > 100 ml/m2 had a sifnificant higher peri- and postoperative mortality than patients with LVEDVI < 100 ml/m2. Mean LVEDVI of those patients, whose LVEF increased postoperatively, was 84 ml/m2. Patients with no change in LVEF had a mean LVEDVI of 122 ml/m2. Conclusion: CABG in patients with reduced LVEF improves exercise tolerance and quality of life. Poor LVEF (< 30%) and augmented LVEDVI are predicting higher peri- and postopertive mortality. Postoperative increase of LVEF is unlikely in patients with enlarged left ventricels.